Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $126.00.

LNTH has been the subject of a number of recent analyst reports. B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. JMP Securities decreased their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Finally, Truist Financial decreased their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st.

Lantheus Trading Up 1.5 %

Shares of NASDAQ:LNTH opened at $105.55 on Wednesday. The stock has a market capitalization of $7.33 billion, a price-to-earnings ratio of 16.11 and a beta of 0.50. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a 50 day moving average price of $104.91 and a 200 day moving average price of $82.74.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 earnings per share. On average, research analysts anticipate that Lantheus will post 5.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Insiders sold a total of 40,852 shares of company stock worth $3,922,001 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. International Assets Investment Management LLC bought a new position in Lantheus in the 4th quarter worth $407,000. M&T Bank Corp acquired a new position in Lantheus during the 4th quarter worth $320,000. Charles Schwab Investment Management Inc. lifted its position in Lantheus by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider’s stock worth $52,077,000 after acquiring an additional 7,590 shares during the last quarter. Principal Securities Inc. acquired a new position in Lantheus during the 4th quarter worth $28,000. Finally, Qsemble Capital Management LP acquired a new position in Lantheus during the 4th quarter worth $210,000. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.